Lassa fever

Lassa fever
Name	Lassa fever
Field	Infectious disease

Lassa fever Lassa fever is an acute viral hemorrhagic illness first described in Nigeria in the 1960s and later linked to outbreaks in multiple West Africaan countries. The disease has been investigated by teams from institutions such as the Centers for Disease Control and Prevention, World Health Organization, and Médecins Sans Frontières, with research published in journals associated with Johns Hopkins University and Harvard University. Clinical and public health responses have involved collaborations among agencies like the National Institutes of Health, Wellcome Trust, and Coalition for Epidemic Preparedness Innovations.

Overview

Lassa fever is caused by an arenavirus identified during investigations at Lagos University Teaching Hospital and linked to field studies in rural Sierra Leone and Guinea. Historical work by researchers connected to Yale University and Liverpool School of Tropical Medicine characterized the clinical syndrome and zoonotic cycle. Outbreaks have prompted emergency responses coordinated with African Union health bodies and regional centers such as the West African Health Organization. International policy discussions have included United Nations agencies and national ministries of health across Benin, Liberia, and Nigeria.

Virology and Transmission

The etiologic agent is an arenavirus closely related to other members studied at laboratories like the Bernhard Nocht Institute for Tropical Medicine and the Pasteur Institute. Reservoir-host ecology involves the multimammate rat species identified in ecological surveys by teams from University of Oxford and University of Cambridge. Human transmission occurs via exposure documented in reports by Centers for Disease Control and Prevention: contact with rodent urine or feces, ingestion of contaminated food, or direct exposure described in clinical case series associated with institutions such as Imperial College London. Nosocomial spread has been documented in hospitals like those affiliated with Ahmadu Bello University and necessitated infection control guidance from World Health Organization and Pan American Health Organization-linked projects. Laboratory studies by Rockefeller University and Brown University have examined viral entry mechanisms and genetic variation.

Signs and Symptoms

Clinical descriptions originate from case reports in facilities including Irrua Specialist Teaching Hospital and reference texts produced by Oxford University Press and Cambridge University Press. Early symptoms resemble presentations detailed in differential diagnosis protocols used by clinicians at University College London Hospitals and include fever, malaise, and sore throat. Progression to more severe features—facial swelling, hemorrhage, and respiratory distress—has been described in cohort analyses from Federal Medical Centre, Lokoja and comparative reviews by Columbia University. Neurological manifestations reported in studies from Karolinska Institutet and University of Toronto include hearing loss and encephalopathy.

Diagnosis and Laboratory Testing

Diagnostic algorithms recommended by World Health Organization and implemented at reference labs such as National Institute for Communicable Diseases rely on molecular assays, antigen detection, and serology developed in collaborations with Imperial College London and the European Centre for Disease Prevention and Control. Reverse transcription PCR protocols validated at Centers for Disease Control and Prevention and National Institutes of Health provide early confirmation, while enzyme-linked immunosorbent assays used in field studies by Médecins Sans Frontières and Wellcome Trust teams support serosurveys. Viral culture work performed under containment at facilities like Rockefeller University and Pasteur Institute informs biosafety guidance from International Labour Organization and World Health Organization committees.

Treatment and Management

Clinical management principles draw on randomized or observational studies conducted with partners including Johns Hopkins University, Yale University, and University of Ibadan. Antiviral therapy with ribavirin—assessed in trials supported by National Institutes of Health—is used in some severe cases, with dosing regimens referenced in treatment guidelines developed by World Health Organization and national ministries such as Nigeria Centre for Disease Control. Supportive care strategies implemented in treatment centers like Irrua Specialist Teaching Hospital include fluid management, ventilatory support, and hemodynamic monitoring, reflecting protocols from Massachusetts General Hospital and Guy's and St Thomas' NHS Foundation Trust. Clinical research networks coordinated by Coalition for Epidemic Preparedness Innovations and academic partners continue to evaluate novel therapeutics and monoclonal antibody candidates investigated at University of California, San Francisco and Duke University.

Prevention and Control

Prevention efforts emphasize rodent control programs promoted by agencies such as United Nations Environment Programme and community engagement models developed by Médecins Sans Frontières and Tony Blair Institute for Global Change-supported initiatives. Vaccination research led by consortia including Coalition for Epidemic Preparedness Innovations, Wellcome Trust, and biotechnology companies in collaboration with National Institutes of Health aims to develop immunization strategies evaluated in clinical trials overseen by regulatory authorities like the European Medicines Agency and United States Food and Drug Administration. Infection prevention in healthcare settings follows protocols from World Health Organization, Centers for Disease Control and Prevention, and hospital systems such as Oxford University Hospitals NHS Foundation Trust.

Epidemiology and Public Health Impact

Endemic transmission occurs across countries in West Africa with surveillance data compiled by World Health Organization, Africa Centres for Disease Control and Prevention, and national bodies like Nigeria Centre for Disease Control. Outbreaks have affected communities monitored by humanitarian organizations including International Committee of the Red Cross, United Nations Children's Fund, and Doctors Without Borders operations. Economic and health-systems analyses involving researchers from Harvard University, London School of Hygiene & Tropical Medicine, and University of Ghana assess burden, case-fatality ratios, and long-term sequelae such as sensorineural hearing loss documented in cohort studies from Irrua Specialist Teaching Hospital and Kenema Government Hospital. Global health policy fora at World Health Assembly and G7 health working groups have discussed resource mobilization and research prioritization.

Category:Viral hemorrhagic fevers